CD38 and acute myeloid leukemia: Since CD38 is also expressed by T and NK cells leading to fratricide, a previous study used an anti‐CD38 antibody to reduce fratricide through cross‐linking anti‐CD38 CAR with intrinsic CD38.[27] Alternatively, gene editing by CRISPR/Cas9 was used to disrupt the CD38 gene of NK cells to reduce fratricide during the treatment of AML.[28] Besides T and NK cells, CD38 is also expressed in other hematological cells like precursor B cells, plasma cells, and non‐hematological tissue.